Skip to main content

Table 2 Univariate and Multivariate Analysis of YAP1/FAPα, and Clinical Characteristics for Recurrence-Free Survival of NPC Patients

From: Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts

YAP1 Univariate analysis   Multivariate analysis  
n = 106 HR (95% CI) p value HR (95% CI) p value
YAP1 Score (≥80 vs. < 80) 2.255 (0.899–5.653) 0.083 3.841 (1.356–10.883) 0.011
Treatment Daysa 1.099 (0.996–1.212) 0.06 1.203 (1.073–1.349) 0.002
BEDa 0.943 (0.805–1.103) 0.46 0.884 (0.743–1.052) 0.164
Age Group (≥48 vs. < 48) 0.641 (0.262–1.568) 0.329 0.433 (0.133–1.416) 0.166
Gender (Male vs. Female) 1.642 (0.549–4.912) 0.375 1.631 (0.409–6.501) 0.488
T-Stage (T3/4 vs. T1/2) 2.043 (0.815–5.123) 0.128 5.354 (1.416–20.249) 0.013
N-Stage (N2/3 vs. N0/1) 1.541 (0.638–3.719) 0.336 1.388 (0.484–3.979) 0.541
Chemotherapy (Yes vs. No) 0.649 (0.249–1.690) 0.376 0.620 (0.208–1.849) 0.391
Comorbidity (Yes vs. No) 0.905 (0.361–2.269) 0.832 1.825 (0.579–5.752) 0.304
Smoking (Yes vs. No) 1.384 (0.566–3.386) 0.477 1.242 (0.384–4.020) 0.717
Betel quid (Yes vs. No) 2.361 (0.941–5.925) 0.067 0.769 (0.201–2.940) 0.702
Alcohol (Yes vs. No) 3.478 (1.386–8.727) 0.008 4.211 (1.217–14.574) 0.023
FAPα Univariate analysis   Multivariate analysis  
n = 143 HR (95% CI) p value HR (95% CI) p value
FAPα Score (≥80 vs. < 80) 1.259 (0.528–2.946) 0.595 1.415 (0.519–3.857) 0.497
Treatment Daysa 1.124 (1.046–1.209) 0.002 1.170 (1.063–1.288) 0.001
BEDa 1.046 (0.958–1.143) 0.313 1.060 (0.967–1.162) 0.216
Age Group (≥48 vs. < 48) 0.888 (0.385–2.049) 0.781 0.806 (0.293–2.219) 0.677
Gender (Male vs. Female) 1.311 (0.484–3.555) 0.594 0.749 (0.237–2.373) 0.624
T-Stage (T3/4 vs. T1/2) 2.209 (0.900–5.420) 0.084 2.339 (0.798–6.854) 0.121
N-Stage (N2/3 vs. N0/1) 2.428 (0.990–5.955) 0.053 2.176 (0.823–5.753) 0.117
Chemotherapy (Yes vs. No) 0.648 (0.253–1.656) 0.365 0.496 (0.164–1.500) 0.214
Comorbidity (Yes vs. No) 1.273 (0.519–3.123) 0.598 1.570 (0.569–4.332) 0.383
Smoking (Yes vs. No) 1.777 (0.725–4.359) 0.209 1.015 (0.330–3.125) 0.979
Betel quid (Yes vs. No) 2.135 (0.895–5.092) 0.087 0.947 (0.318–2.824) 0.922
Alcohol (Yes vs. No) 3.664 (1.565–8.577) 0.003 6.015 (1.839–19.669) 0.003
  1. acontinuous variable. BED Biologically effective dose, HR Hazard ratio, CI Confidence interval